We Claim:

1. Use of an anti-CD19 antibody in the manufacture of a medicament for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma, wherein the medicament is to be administered in combination with venetoclax, wherein the anti-CD19 antibody is to be administered at least 7 days prior to the first administration of venetoclax, and wherein the anti-CD19 antibody comprises an HCDR1 region comprising sequence SYVMH (SEQ ID NO:1), an HCDR2 region comprising sequence NPYNDG (SEQ ID NO:2), an HCDR3 region comprising sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region comprising sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region comprising sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region comprising sequence MQHLEYPIT (SEQ ID NO:6).

2. The use according to claim 1, wherein the anti-CD19 antibody is to be administered weekly, bi-weekly or monthly after a first administration on Day 1 and wherein venetoclax is to be administered for the first time on Day 8.

3. The use according to any one of the preceding claims, wherein the anti-CD19 antibody after a first administration on Day 1 is to be administered weekly for the first 3 months.

4. The use according to claim 3, wherein the anti-CD19 antibody after a first administration on Day 1 is to be administered weekly for the first 3 months and bi-weekly for at least the next 3 months.

5. The use according to claim 4, wherein the anti-CD19 antibody after a first administration on Day 1 is to be administered weekly for the first 3 months, bi-weekly for the next 3 months and monthly thereafter.

6. The use according to any one of the preceding claims, wherein there is an additional dosing of the anti-CD19 antibody on Day 4.

7. The use according to any one of the preceding claims, wherein venetoclax is to be administered for the first time on Day 8 with a starting dose of 20mg followed by a weekly ramp-up dosing of 50mg, 100mg, 200mg and 400mg, optionally followed by a daily dosing of 400mg.

8. The use according to any one of the preceding claims, wherein said anti-CD19 antibody and venetoclax are to be administered separately.

9. The use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises a variable heavy chain comprising the sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT
KYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTL
VTVSS (SEQ ID NO: 10)
and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID
NO: 11).

10. The use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises a heavy chain constant domain comprising the sequence
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

11. The use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises a light chain constant domain comprising the sequence

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 13).

12. The use according to any one of the preceding claims, wherein the anti-CD19 antibody is to be administered in a concentration of 12 mg/kg.

13. The use according to any one of the preceding claims for treating non-Hodgkin’s lymphoma.

14. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is follicular lymphoma.

15. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is mucosa-associated lymphoid tissue lymphoma.

16. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is marginal zone lymphoma.

17. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is diffuse large B cell lymphoma.

18. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is Burkitt's lymphoma.

19. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is mantle cell lymphoma.

20. The use according to any one of claims 1 to 12 for treating chronic lymphocytic leukemia.

21. The use according to any one of claims 1 to 12 for treating small lymphocytic lymphoma.